NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

28.46 +0.50 (+1.79%)
At close: August 31 at 4:01:33 PM EDT
28.45 -0.01 (-0.04%)
Pre-Market: 5:01:02 AM EDT
Trade Pfizer on Coinbase
Chart Range Bar
Loading chart for PFE

What's happening with PFE?

10m ago
Powered by Yahoo Scout

Pfizer (PFE) recently reached a confidential settlement regarding the Depo-Provera litigation, impacting its legal risk outlook. The company's oncology segment shows growth potential, while overall stock performance remains cautious against market benchmarks.

Powered by Yahoo Scout
  • Previous Close 27.96
  • Open 27.85
  • Bid --
  • Ask --
  • Day's Range 27.64 - 28.70
  • 52 Week Range 23.58 - 28.75
  • Volume 45,442,575
  • Avg. Volume 42,216,912
  • Market Cap (intraday) 162.213B
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) 36.96
  • EPS (TTM) 0.77
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield 1.72 (6.15%)
  • Ex-Dividend Date Jul 24, 2026
  • 1y Target Est 28.61

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

75,000

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PFE
20.20%
S&P 500 (^GSPC)
12.28%

1-Year Return

PFE
23.00%
S&P 500 (^GSPC)
18.98%

3-Year Return

PFE
2.44%
S&P 500 (^GSPC)
70.51%

5-Year Return

PFE
19.51%
S&P 500 (^GSPC)
69.95%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 15.03B
Earnings -248M
Profit Margin -1.65%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
5B
10B
15B
0.0%
10.0%
20.0%
 

Analyst Insights

View More

Top Analyst

JP Morgan
46/100
Latest Rating
Neutral
 

Analyst Price Targets

25.00 Low
28.61 Average
28.46 Current
35.75 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 8/7/2026
Analyst Guggenheim
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 35 -> 31
 

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    159.70B

  • Enterprise Value

    211.20B

  • Trailing P/E

    36.87

  • Forward P/E

    9.50

  • PEG Ratio (5yr expected)

    2.71

  • Price/Sales (ttm)

    2.52

  • Price/Book (mrq)

    1.87

  • Enterprise Value/Revenue

    3.32

  • Enterprise Value/EBITDA

    15.65

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.80%

  • Return on Assets (ttm)

    5.78%

  • Return on Equity (ttm)

    5.01%

  • Revenue (ttm)

    63.7B

  • Net Income Avi to Common (ttm)

    4.34B

  • Diluted EPS (ttm)

    0.77

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.7B

  • Total Debt/Equity (mrq)

    74.25%

  • Levered Free Cash Flow (ttm)

    12.49B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

28.46 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 08/13/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • US Large Cap Pick List - August 2026

    This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.

     
  • Strong growth from non-COVID products

    Pfizer is a leading developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.

    Rating
    Price Target
     
  • The market took a much-needed rest on Wednesday, which

    The market took a much-needed rest on Wednesday, which is a technical a positive. The last thing we need is a parabolic, blow-off move. While the rally was only four days, investors may have been chasing returns. The best action that can endure for the longest time is a simple crawl higher (never too hot or too cold). Parabolic advances typically are ending moves (just look at what happened to metals, crypto currencies, and some semiconductor stocks this year).

     

People Also Watch